Literature DB >> 12675279

Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation.

Kazuhide Ayajiki1, Hideyuki Fujioka, Noboru Toda, Shigeru Okada, Yukiko Minamiyama, Susumu Imaoka, Yoshihiko Funae, Shuji Watanabe, Akio Nakamura, Tomio Okamura.   

Abstract

We investigated mechanisms of endothelium-dependent relaxation by acetylcholine resistant to indomethacin and N(G)-nitro-L-arginine and sensitive to cytochrome P-450 (CYP) inhibitors or charybdotoxin + apamin in the monkey lingual artery. Treatment with quinacrine, an inhibitor of phospholipase A2, abolished the relaxation by acetylcholine. However, treatment with alpha-glycyrrhetinic acid, an inhibitor of gap junctions, or catalase, an enzyme which dismutates hydrogen peroxide to form water and oxygen, did not affect the relaxation by acetylcholine. Immunohistochemistry demonstrated the presence of CYP3A4 in endothelial cells of the artery. Anti-CYP3A4 antibody inhibited relaxations by products of arachidonic acid incubated with human liver microsomes rich in CYPs in the endothelium-denuded artery. Purified CYP3A4 produced epoxyeicosatrienoic acids (EETs) from arachidonic acid, and the production was abolished by a selective CYP3A inhibitor, ketoconazole. It may be concluded that endothelium-derived relaxing substance(s) other than nitric oxide and prostanoids in the monkey lingual artery opens charybdotoxin + apamin-sensitive K+ channels in smooth muscle cells, and arachidonic acid metabolite(s) produced by endothelial CYP3A4 is likely to be the major substance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675279     DOI: 10.1291/hypres.26.237

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  7 in total

Review 1.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).

Authors:  Ranjana Mitra; Zhijun Guo; Monica Milani; Clementina Mesaros; Mariangellys Rodriguez; Julia Nguyen; Xianghua Luo; Duncan Clarke; Jatinder Lamba; Erin Schuetz; David B Donner; Narender Puli; John R Falck; Jorge Capdevila; Kalpna Gupta; Ian A Blair; David A Potter
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

3.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

4.  Statins and selective inhibition of Rho kinase protect small conductance calcium-activated potassium channel function (K(Ca)2.3) in cerebral arteries.

Authors:  Alister J McNeish; Francesc Jimenez-Altayo; Graeme S Cottrell; Christopher J Garland
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

5.  CYP3A4 and CYP11A1 variants are risk factors for ischemic stroke: a case control study.

Authors:  Ning Gao; Hong Tang; Ling Gao; Guolong Tu; Han Luo; Ying Xia
Journal:  BMC Neurol       Date:  2020-03-04       Impact factor: 2.474

6.  N-3 Polyunsaturated Fatty Acids Decrease the Protein Expression of Soluble Epoxide Hydrolase via Oxidative Stress-Induced P38 Kinase in Rat Endothelial Cells.

Authors:  Takashi Okada; Katsutaro Morino; Fumiyuki Nakagawa; Masashi Tawa; Keiko Kondo; Osamu Sekine; Takeshi Imamura; Tomio Okamura; Satoshi Ugi; Hiroshi Maegawa
Journal:  Nutrients       Date:  2017-06-24       Impact factor: 5.717

7.  Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer.

Authors:  Nguyen Thi Thuy Phuong; Ji Won Kim; Jung-Ae Kim; Jang Su Jeon; Ji-Yoon Lee; Wen Jun Xu; Jin Won Yang; Sang Kyum Kim; Keon Wook Kang
Journal:  Oncotarget       Date:  2017-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.